About US
Contact us
-
Arena narrows loss as Belviq sales pick upArena Pharmaceuticals ($ARNA), developer of the weight-loss drugBelviq, is not exactly getting fat off of its sales, but it is making progress. With a marketing push from partnerEisaibehind it, the dr2014/11/5
-
Eleventh API China pharmaceutical excipients ForumEleventh API China pharmaceutical excipients Forum Pharmaceutical excipients and food additives’ quality standard seminar Time: November 28, 2014 9: 00-16: 30 Venue: China Import and Export Fa2014/11/5
-
2014'PHEXTOUR– Zhuhai Station2014'PHEXTOUR Pharmaceutical Excipients Application Technology (Greater China) Tour Seminars– Zhuhai Station Publisher: phexcom Published: 2014/10/28 10:42:08 2014'PHEXTOUR Pharmaceutical Excipie2014/11/4
-
Bristol-Myers Squibb expands biologics manufacturing agreement with LonzaBristol-Myers Squibb (BMS) has expanded its existing biologics manufacturing agreement with Switzerland-based Lonza. The contract is expanded for the production of commercial quantities of a second B2014/11/4
-
Genmab signs ofatumumab transfer agreement with GSK and NovartisDenmark-based Genmab has signed an agreement with British drug-maker GlaxoSmithKline (GSK) and Swiss pharmaceutical company Novartis for the conditional transfer of ofatumumab collaboration contract f2014/11/4
-
CFDA, General Administration of Customs and General Administration of Sport jointly issue Administrative Measures for Import and Export of Anabolic Agents and Peptide HormonesIn accordance with the relevant requirements of the State Council on deepening the reform of administrative approval system, the approval of the import of anabolic agents and peptide hormones is autho2014/11/4
-
British-Swedish drugmaker AstraZeneca has received approval from US Food and Drug Administration (FDA) for its once-daily Xigduo XR to treat adult patients with type 2 diabetes.British drug-maker GlaxoSmithKline (GSK) has introduced a new once-daily bronchodilator treatment, Incruse Ellipta (umeclidinium) in the UK. A long-acting muscarinic antagonist (LAMA), Incruse has be2014/11/3
-
AstraZeneca’s type 2 diabetes treatment Xigduo XR obtains FDA approvalBritish-Swedish drugmaker AstraZeneca has received approval from US Food and Drug Administration (FDA) for its once-daily Xigduo XR to treat adult patients with type 2 diabetes. Xigduo XR is a combin2014/11/3
-
Pfizer’s Trumenba gets FDA accelerated approval to treat Meningococcal B diseaseUS-based drugmaker Pfizer has received accelerated approval from US Food and Drug Administration (FDA) for its Trumenba to treat Meningococcal B disease in adolescents and young adults. As part of th2014/11/3
-
Qiagen and Astellas Pharma to develop companion diagnostics for cancer and other diseasesQiagen has signed a master collaboration agreement with global pharmaceutical company Astellas Pharma to develop and commercialise companion diagnostics, combined with the latter's drugs for use in ca2014/10/31